Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer

• Principais autores: Shengya Fu (Autor), Linjuan Li (Autor), Xiaofen Li (Autor), Qiang Wu (Autor), Xiaohui Wang (Autor), Yan Huang (Autor), Haoyue Hu (Autor), Dan Cao (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Gastric cancer is the second most prevalent cancer and the second leading cause of cancer-related death in China. The prognosis of metastatic gastric cancer is poor with a median overall survival of 8-10 months. Apatinib, an oral small-molecule, selective vascular endothelial growth factor receptor-...